Nicotinamide derivatives useful as p38 inhibitors.
Compounds of formula (I): are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.
1. A compound of formula (I):
wherein
R 1 is selected from hydrogen, C 1-6 alkyl optionally substituted by up to three groups selected from C 1-6 alkoxy, halogen and hydroxy, C 2-6 alkenyl, C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, phenyl optionally substituted by up to three groups selected from R 5 and R 6 , and heteroaryl optionally substituted by up to three groups selected from R 5 and R 6 ,
R 2 is selected from hydrogen, C 1-6 alkyl and —(CH 2 ) q —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups,
or (CH 2 ) m R 1 and R 2 , together with the nitrogen atom to which they are bound, form a four- to six-membered heterocyclic ring optionally substituted by up to three C 1-6 alkyl groups;
R 3 is chloro or methyl;
R 4 is the group —NH—CO—R 7 or —CO—NH—(CH 2 ) q —R 8 ;
R 5 is selected from C 1-6 alkyl, C 1-6 alkoxy, —(CH 2 ) q —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, —CONR 9 R 10 , —NHCOR 10 , —SO 2 NHR 9 , —(CH 2 ) S NHSO 2 R 10 , halogen, CN, OH, —(CH 2 ) S NR 11 R 12 , and trifluoromethyl;
R 6 is selected from C 1-6 alkyl, C 1-6 alkoxy, halogen, trifluoromethyl and —(CH 2 ) S NR 11 R 12 ;
R 7 is selected from hydrogen, C 1-6 alkyl, —(CH 2 ) q —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, trifluoromethyl, —(CH 2 ) r heteroaryl optionally substituted by R 13 and/or R 14 , and —(CH 2 ) r phenyl optionally substituted by R 13 and/or R 14 ;
R 8 is selected from hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, CONHR 9 , phenyl optionally substituted by R 13 and/or R 14 , and heteroaryl optionally substituted by R 13 and/or R 14 ;
R 9 and R 10 are each independently selected from hydrogen and C 1-6 alkyl,
or R 9 and R 10 , together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R 15 , wherein the ring may be substituted by up to two C 1-6 alkyl groups;
R 11 is selected from hydrogen, C 1-6 alkyl and —(CH 2 ) q —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups,
R 12 is selected from hydrogen and C 1-6 alkyl,
or R 11 and R 12 , together with the nitrogen atom to which they are bound, form a five or six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N—R 15 ;
R 13 is selected from C 1-6 alkyl, C 1-6 alkoxy, —(CH 2 ) q —C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, —CONR 9 R 10 , —NHCOR 10 , halogen, CN, —(CH 2 ) S NR 11 R 12 , trifluoromethyl, phenyl optionally substituted by one or more R 14 groups and heteroaryl optionally substituted by one or more R 14 groups;
R 14 is selected from C 1-6 alkyl, C 1-6 alkoxy, halogen, trifluoromethyl and —NR 11 R 12 ;
R 15 is selected from hydrogen and methyl;
X and Y are each independently selected from hydrogen, methyl and halogen;
Z is halogen;
m is selected from 0, 1, 2, 3 and 4, wherein each carbon atom of the resulting carbon chain may be optionally substituted with up to two groups selected independently from C 1-6 alkyl and halogen;
n is selected from 0, 1 and 2;
q is selected from 0, 1 and 2;
r is selected from 0 and 1; and
s is selected from 0, 1, 2 and 3, or
a pharmaceutically acceptable salt or solvate thereof.
2. A compound according to claim 1 wherein R 1 is selected from C 1-6 alkyl, C 2-6 alkenyl, C 3-7 cycloalkyl optionally substituted by one or more C 1-6 alkyl groups, phenyl optionally substituted by up to three substituents selected from R 5 and R 6 , heteroaryl optionally substituted by up to three substituents selected from R 5 and R 6 .
3. A compound according to claim 1 wherein R 2 is hydrogen.
4. A compound according to claim 1 wherein R 3 is methyl.
5. A compound according to claim 1 wherein X is fluorine.
6. A compound according to claim 1 wherein R 7 is selected from C 1-6 alkyl, —(CH 2 ) q —C 3-7 cycloalkyl, trifluoromethyl, —(CH 2 ) r heteroaryl optionally substituted by R 13 and/or R 14 , and —(CH 2 ) r phenyl optionally substituted by C 1-6 alkyl, C 1-16 alkoxy, —(CH 2 ) q —C 3-7 cycloalkyl, —CONR 9 R 10 , —NHCOR 10 , halogen, CN, trifluoromethyl, phenyl optionally substituted by one or more R 14 groups and/or heteroaryl optionally substituted by one or more R 14 groups.
7. A compound according to any claim 1 wherein R 8 is selected from C 3-7 cycloalkyl, CONHR 9 , heteroaryl optionally substituted by R 13 and/or R 14 , and phenyl optionally substituted by C 1-6 alkyl, C 1-6 alkoxy, —(CH 2 ) q —C 3-7 cycloalkyl, —CONR 9 R 10 , —NHCOR 10 , halogen, CN, trifluoromethyl, phenyl optionally substituted by one or more R 14 groups and/or heteroaryl optionally substituted by one or more R 14 groups.
8. A compound according to claim 1 as defined in any one of Examples 1 to 123.
9. A pharmaceutical composition comprising a compound, pharmaceutically acceptable salt or solvate thereof, according to claim 1 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.
10. A compound which is 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl)-nicotinamide, or a pharmaceutically acceptable salt of solvate thereof.
11. A compound which is 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl)-nicotinamide.
12. A pharmaceutical composition comprising an effective amount of a compound, or a pharmaceutically acceptable salt of solvate thereof according to claim 10 , in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.
13. A pharmaceutical composition comprising an effective amount of a compound according to claim 11 , in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.
14. A method of treating inflammation in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound, or a pharmaceutically acceptable salt or solvate thereof, according to claim 1 .
15. A method of treating inflammation in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound, or a pharmaceutically acceptable salt or solvate thereof, according to claim 10 .